# **FACT SHEET**

# MANULIFE DANA EKUITAS CHINA DOLAR

MAR 2025

# Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies domiciled in the People's Republic of China (PRC) as well as other companies that have close economic links with the PRC, onshore and/or offshore, directly and/or through mutual funds.


# **Fund Information**

22 Mar 21 Inception Price USD 1.0000 Fund Size USD 603,741.53 1,079,290.60 Number of unit USD 0.5594 Net Asset Value/Unit 3) Fund Currency USD Type of fund Equity Valuation Daily

Custodian Bank Bank DBS Indonesia Annual Management Fee 2.50% Bloomberg Code MAECDMU IJ

Fund Manager PT Manulife Aset Manajemen Indonesia

## **Risk Classification**



32.00%

23.00% 14.00%

-4 00%

-13.00%

-22.00%

Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).

**Monthly Performance Last 3 Years** 


2) The benchmark is MSCI Golden Dragon Index.

Sep-22

Mar-23

3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording

## **Performance Since Inception**



**Fund Performance** 

Performance in USD per (27/03/25)												
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr <sup>1)</sup>	5 yr <sup>1)</sup>	Since Inception 1)				
MADENA	3.91%	11.78%	-0.13%	11.78%	22.16%	-4.83%	n/a	-13.47%				
BM <sup>2)</sup>	0.17%	6.19%	2.30%	6.19%	26.05%	1.40%	n/a	-5.28%				


Yearly Performance												
	2024	2023	2022	2021	2020	2019	2018	2017				
MADENA	6.41%	-15.76%	-23.41%	n/a	n/a	n/a	n/a	n/a				
BM 2)	20.05%	-3.45%	-23.53%	n/a	n/a	n/a	n/a	n/a				

Sep-23

Mar-24

# Top Holdings\* & Sector Allocation

Mutual Fund - UBS Lux Equity SICAV - All China USD



Mutual Fund - Equity

Sep-24 Mar-25

Cash & Deposit

In March, China equities extended gains although it traded within a narrow range in March. After a period of strong performance, investors tactically took profits towards the end of March in anticipation of further US tariff announcements on 'Liberation Day'. Economic data showed improvements, with manufacturing PMI expanding further in March, adding to the rise in February. Chinese exports remained resilient in first quarter, even though export to the US have dropped, the decline was partially offset by a rise in exports to EM Asia countries. Industrial production, retail sales and fixed asset investment also came in strong in the month. Major increases in US tariffs surprised markets in both their scale and punitive nature. The new US tariffs can be a major drag on China's recovery, making it nearly impossible to meet growth expectations set for the year. However, we believe that there is room for Chinese policymakers to accelerate deployment of stimulus, such as the continued front-loading of fiscal resources and resumption of monetary easing. Despite these challenges, it is worth highlighting that Chinese equities have the lowest exposure to foreign revenue relative to other countries impacted. We take an active approach to stock selection to minimize any impact from trade issues such as electronics, machinery, automobile and textile. All in all, we maintain our positions in high-quality, domestically-focused companies.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

nulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit









